Canaccord raised the firm’s price target on AxoGen (AXGN) to $26 from $22 and keeps a Buy rating on the shares. The firm said they posted strong Q4 results as the company notes its positive performance reflects ongoing improvements in commercial execution, including its focus on high-potential accounts along with adoption of AXGN’s algorithm across procedures.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN: